Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30165657 | 0.77 | TSHR (0.33) | TSHRMAPK1HSD17B10TDP1 | |
| SCHEMBL21226686 | 0.73 | — | — | |
| SCHEMBL6660448 | 0.72 | TSHR (0.33) | TSHRMAPK1HSD17B10TDP1 | |
| SCHEMBL7102475 | 0.72 | TSHR (0.30) | TSHRMAPK1HSD17B10TDP1 | |
| SCHEMBL28551354 | 0.69 | HCAR2 (0.33) | HSD17B10 | |
| SCHEMBL22826713 | 0.66 | — | — | |
| SCHEMBL22753318 | 0.64 | POLB (0.31) | TSHR | |
| SCHEMBL967282 | 0.64 | — | — | |
| SCHEMBL21401201 | 0.60 | — | — | |
| SCHEMBL30932999 | 0.58 | ALDH1A1 (0.33) | HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170805-B1 | METHODS OF SYNTHESIZING CINACALCET AND SALTS THEREOF | AMGEN INC (US) | 2016-03-16 | — | — | EP | disclosed |
| US-8183415-B2 | Methods of synthesizing cinacalcet and salts thereof | AMGEN, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20110281954-A1 | METHODS OF SYNTHESIZING CINACALCET AND SALTS THEREOF | AMGEN INC. | 2011-11-17 | — | — | US | disclosed |
| EP-2170805-A2 | METHODS OF SYNTHESIZING CINACALCET AND SALTS THEREOF | Amgen Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20090137837-A1 | METHODS OF SYNTHESIZING CINACALCET AND SALTS THEREOF | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| WO-2009002427-A2 | METHODS OF SYNTHESIZING CINACALCET AND SALTS THEREOF | AMGEN INC. (US) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137837-A1 | METHODS OF SYNTHESIZING CINACALCET AND SALTS THEREOF | ACE, SI, REN | TSHR 3980/4885MAPK1 4445/4885HSD17B10 3133/4885 |
| US-20110281954-A1 | METHODS OF SYNTHESIZING CINACALCET AND SALTS THEREOF | ACE, SI, REN | TSHR 3980/4885MAPK1 4445/4885HSD17B10 3133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.